384 related articles for article (PubMed ID: 17976085)
1. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism.
Kazama JJ
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S44-7. PubMed ID: 17976085
[TBL] [Abstract][Full Text] [Related]
2. Attainment of the Japanese Society for Dialysis Therapy guidelines for the management of secondary hyperparathyroidism in chronic hemodialysis patients in our clinic.
Sato Y; Eriguchi R; Umakoshi J; Kato M
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S48-53. PubMed ID: 17976086
[TBL] [Abstract][Full Text] [Related]
3. Achievement of the Japanese Society for Dialysis Therapy guideline targets for mineral metabolism measures: one Japanese university center result.
Kimata N; Miwa N; Otsubo S; Iwasaki T; Yabuki Y; Miyabe K; Asamiya Y; Sato K; Sugi O; Ikebe N; Kiuchi K; Mineshima M; Akiba T
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S62-6. PubMed ID: 17976088
[TBL] [Abstract][Full Text] [Related]
4. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study.
Komaba H; Fukagawa M;
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S44-9. PubMed ID: 19032527
[TBL] [Abstract][Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. Calcium and phosphorus control in patients undergoing hemodialysis: from the view-points of activities of daily living.
Osawa Y
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S54-61. PubMed ID: 17976087
[TBL] [Abstract][Full Text] [Related]
7. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764
[TBL] [Abstract][Full Text] [Related]
8. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients.
Guideline Working Group, Japanese Society for Dialysis Therapy
Ther Apher Dial; 2008 Dec; 12(6):514-25. PubMed ID: 19140852
[No Abstract] [Full Text] [Related]
9. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
[TBL] [Abstract][Full Text] [Related]
10. The need for better control of secondary hyperparathyroidism.
Locatelli F
Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V15-19. PubMed ID: 15284355
[TBL] [Abstract][Full Text] [Related]
11. Challenges in the therapy of secondary hyperparathyroidism.
Wood C; González EA; Martin KJ
Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
[TBL] [Abstract][Full Text] [Related]
12. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
13. Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D.
Fukagawa M; Komaba H; Onishi Y; Fukuhara S; Akizawa T; Kurokawa K;
Am J Nephrol; 2011; 33(5):427-37. PubMed ID: 21508631
[TBL] [Abstract][Full Text] [Related]
14. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
[TBL] [Abstract][Full Text] [Related]
15. Mineral metabolism disturbances in patients with chronic kidney disease.
Kestenbaum B; Belozeroff V
Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
[TBL] [Abstract][Full Text] [Related]
16. [Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate].
Aresté N; Amor J; Cambil T; Salgueira M; Sánchez-Palencia R; Páez C; Gómez O; Palma A
Nefrologia; 2003; 23 Suppl 2():64-8. PubMed ID: 12778857
[TBL] [Abstract][Full Text] [Related]
17. [Secondary hyperparathyroidism in renal insufficiency. Prevention and therapy].
Malluche HH; Ritz E
MMW Munch Med Wochenschr; 1976 Jan; 118(5):129-30. PubMed ID: 814442
[No Abstract] [Full Text] [Related]
18. [Secondary hyperparathyroidism: incidence, clinical presentations, treatment].
Samokhvalova NA; Romanchishen AF; Gerasimchuk RP; Grinev KM; Zemchenkov AIu
Vestn Khir Im I I Grek; 2007; 166(5):78-81. PubMed ID: 18154100
[TBL] [Abstract][Full Text] [Related]
19. [Recent advances in the prevention of cardiovascular morbidity and mortality in end-stage renal disease: role of anemia, hyperparathyroidism and calcifications].
Del Vecchio L; Pozzoni P; Limardo M; Caruso S; Fortunato M; Pontoriero G; Locatelli F
G Ital Nefrol; 2007; 24 Suppl 38():25-32. PubMed ID: 17922444
[TBL] [Abstract][Full Text] [Related]
20. [Control of calcium and phosphate in hemodialysis patients].
Eriguchi R; Takei S; Satou Y
Clin Calcium; 2005 Sep; 15 Suppl 1():132-7; discussion 137. PubMed ID: 16272645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
